Composition for topical use in the form of a gel containing mineral water

Abstract

To provide a system that can achieve a particularly high viscosity level for local use to human or animal skin in the presence of biological active drugs.SOLUTION: A composition for local use in the form of gel (C1) comprises water having a conductivity of 300 microsiemens / cm (μS cm-1) or more when measured at 25°C, a crosslinked anionic polymer electrolyte (P1), and at least one galactomannan (GM).SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a composition for topical use in the form of a gel, comprising water that is at least moderately mineralized, so that it has a conductivity of at least 200 μS / cm measured at 25° C., and which has an efficient thickening system. [Background technology]

[0002] The cosmetics industry uses water of various qualities to prepare cosmetic formulations for sale to end consumers, including natural mineral water, seawater, spring water, terrestrial plant water, and algae water.

[0003] These various waters differ, inter alia, in their geographical and geological origins and, consequently, in their mineralogy. Therefore, water can be characterized by its "total mineralization," i.e., the sum of all mineral elements present in the water under consideration. More specifically, it is a matter of the sum of the amounts of cations and anions present in the water. The cations present in mineral waters are calcium, magnesium, sodium, potassium, iron, zinc, copper, aluminum, and manganese. The anions present in mineral waters are carbonate, bicarbonate, silicate, sulfate, chloride, nitrate, phosphate, and fluoride. Consequently, the concept of "total mineralization" is expressed in units of mass per unit volume, specifically milligrams per liter.

[0004] This mineralization property may be reassessed by measuring the electrical conductivity of said water, which is generally expressed in microsiemens / centimeter (μS / cm) or millisiemens / cm (mS / cm).

[0005] As used herein, the term "low-mineral water" means water having a conductivity of less than 200 μS / cm measured at 25°C.

[0006] As used herein, the term "medium mineral water" means water having a conductivity measured at 25°C of 200 μS / cm or more and less than 333 μS / cm.

[0007] As used herein, the term "Nakagami mineral water" refers to water having a conductivity measured at 25°C of 333 μS / cm or more and less than 666 μS / cm.

[0008] As used herein, the term "high mineral water" refers to water having a conductivity measured at 25°C of 666 μS / cm or more and less than 1000 μS / cm.

[0009] As used herein, the term "highly mineralized water" means water having a conductivity of 1000 μS / cm or greater measured at 25°C.

[0010] Natural mineral waters, seawater, natural spring waters and algal waters are characterized by at least moderate mineralization, i.e., a conductivity of 200 μS / cm or more measured at 25° C., and are often used for the preparation of cosmetic, dermocosmetic, pharmaceutical and dermopharmaceutical compositions for the properties they can provide to human or animal skin.

[0011] Indeed, natural waters, mineral waters, seawater, and algae waters with medium to high mineral content are known to contribute antioxidant, soothing or anti-inflammatory, and allergy-inhibiting properties. It is known in the literature that mineral water is used in formulations to reduce the loss of elasticity of human skin. EP 1170002 A1 describes a method for reducing the loss of elasticity of human skin, including the use of mineral water containing a mineral concentration of at least 200 mg / L. Similarly, EP 0699432 A1 describes the use of water with a total mineralization of 700 mg / L or more to relieve skin irritation that may be caused by active agents such as retinoids, benzoyl peroxide, or salicylic acid used in the treatment of acne.

[0012] It is also known that algae water or seawater can be used for the care of skin disorders such as eczema and psoriasis, or to re-establish health after musculotendinous injuries or conditions or sprains.

[0013] Therefore, there is a demonstrated need to carry out long-term topical applications of seawater or algal water, in the presence or absence of biologically active or inactive components, in order to better target the relevant human or animal body zones.

[0014] JP 2000-273033 A describes a composition in the form of a gel containing an active ingredient and a combination of trehalose and carrageenan as gelling agents.

[0015] EP 2756839 describes a composition based on 95% by weight seawater and hydroxyethylmethylcellulose as gelling agent.

[0016] However, these solutions do not allow the preparation of topically acceptable compositions in the form of gels having high viscosities, e.g., 10,000 mPa·s or more (measured at 25° C. with a Brookfield RVT viscometer at speed 5).

[0017] Cosmetic compositions in the form of aqueous gels marketed by the cosmetic and pharmaceutical industries usually contain synthetic thickening polymers to increase the viscosity of the solution so as to obtain a gel that is applied directly or indirectly to the skin.

[0018] The synthetic thickening polymers currently used in these fields are available in two physical forms: powder and liquid. The polymers are prepared by inverse emulsion radical polymerization using surfactants, and are commonly referred to as self-inverting inverse latexes.

[0019] The most commonly known synthetic thickening polymers in powder form include polymers based on acrylic acid or copolymers based on acrylic acid and its esters. For example, Carbopol TM and Pemulen TM Examples of suitable polymers include those sold under the trade name CI 10 ...

[0020] In cosmetics, homopolymers or copolymers based on 2-acrylamido-2-methylpropanesulfonic acid and / or its salts are still used in powder form. These thickening polymers are also used in the Aristoflex TM These powdered synthetic thickeners are sold under the trade name EP 816403, EP 1116733 and EP 1069142. These powdered synthetic thickeners are obtained by precipitating the polymerization; the monomers are dissolved in an organic solvent such as benzene, ethyl acetate, cyclohexane or tert-butanol; therefore, this process is used to remove traces of residual solvent. Therefore, multiple successive steps are required for purification of the final product.

[0021] The cosmetic and pharmaceutical industries also make very widespread use of thickeners in the liquid form of self-inverting inverse latex, in particular those sold by the applicant, for example the thickener Sepigel TM 305, Simulgel TM 600, Simulgel TM EG, Simulgel TM EPG, Simulgel TM N.S., Simulgel TM A, Sepiplus TM 400, Sepiplus TM 250 and SepiplusTM 265. These thickeners are obtained by inverse emulsion radical polymerization. They have the advantage of being more easily manipulated, especially at room temperature, and dispersing very quickly in water. Furthermore, these products exhibit significantly higher thickening properties; this is likely a result of the process used to prepare them: dispersed-phase radical polymerization, which results in polymers with very high molecular weights.

[0022] The applicant has also developed synthetic thickeners that have thickening qualities comparable to or superior to those of inverse latex, but are better tolerated by the skin, particularly due to the absence of an oil phase, which can result in lighter-colored aqueous gels. These products are in powder form but have dissolution times and, therefore, ease of application comparable to those of liquid-form products. These compounds, described in EP 1 496 081 A1, are obtained via conventional polymerization techniques, such as dispersed-phase radical polymerization, inverse suspension radical polymerization, and inverse emulsion or inverse microemulsion radical polymerization. The resulting synthetic thickening systems are then extracted and purified by various techniques, such as precipitation from an intermediate solvent, followed by optional washing, spray drying, or azeotropic dehydration, and optionally washing with a solvent. These synthetic thickeners thus combine the advantages of synthetic thickeners in standard powder form (absence of oil, production of lighter-colored aqueous gels) with those in inverse latex form (high dissolution rate, significant thickening power, and stabilizing properties). Summary of the Invention [Problem to be solved by the invention]

[0023] However, synthetic thickening polymers such as the cross-linked anionic polyelectrolytes mentioned above are not expected to be sufficiently efficient for use in the presence of water that is at least moderately mineralized and, as a result, has a conductivity of 200 μS / cm or more measured at 25°C.

[0024] Therefore, there remains a need for compositions for topical use that are in the form of gels containing water that are at least moderately mineralized, resulting in a conductivity of at least 200 μS / cm measured at 25° C., and for efficient thickening systems, i.e., systems that make it possible to achieve particularly high viscosity levels for topical use on human or animal skin in the presence of biologically active agents. [Means for solving the problem]

[0025] One solution of the present invention is a composition (C1) for topical use in the form of a gel, comprising: - Conductivity measured at 25°C is 300 microsiemens / centimeter (μS cm -1 ) or more - Crosslinked anionic polyelectrolyte (P1) and - at least one galactomannan (GM).

[0026] As used herein, the term "gel" refers to a chemical composition that is initially in liquid form and that, after the addition of a gelling and / or thickening agent, is transformed into a non-flowing structural state. A gel, as defined, is considered an intermediate state between the solid and liquid states and consists of a three-dimensional network within a liquid as a result of chemical or physical bonds.

[0027] For purposes of the present invention, the term "gelling agent" means a compound or mixture of compounds that converts a liquid medium into a gel.

[0028] For the purposes of the present invention, the term "thickener" means a compound or mixture of compounds that increases the viscosity of the medium into which it is introduced.

[0029] The term "for topical use" as used in the definition of the composition for topical use (C1) as described above means that the composition is used by application to the skin, hair, scalp, nails, lips, mucous membranes, eyelashes or eyebrows, whether this is direct or indirect application in the case of cosmetic preparations, for example in the case of body care products in the form of textile or paper wipes, or hygiene products intended to come into contact with the skin, hair, scalp, nails, lips, mucous membranes, eyelashes or eyebrows.

[0030] The conductivity of the aqueous phase (A1) is measured by directly measuring the current flowing between two electrodes immersed in the aqueous phase (A1) to be measured at a temperature of 25° C. The injected current is an alternating current of very low frequency to avoid polarization of the electrodes.

[0031] The device used consists of a collection box and a probe, which is made up of a temperature electrode, a measuring electrode consisting of two or more sensors or grouped electrode devices.

[0032] The device used is more particularly a WTW brand device, model pH / Cond 34Oi. The measurements are expressed in μS / cm at reference temperature (25° C.).

[0033] The subject of the present invention is 300 μS·cm measured at 25 °C. -1 The aqueous phase (A1) present in the composition (C1) for topical use characterized by a conductivity equal to or greater than this may originate from natural sources and may be used alone or in a mixture with water of another origin.

[0034] present in the composition (C1) for topical use that is the subject of the present invention, and having a conductivity of 300 μS cm, measured at 25 °C -1 The aqueous phase (A1) characterized as described above preferably consists of natural mineral water, natural water, seawater, or algae water.

[0035] Also present in the composition (C1) for topical use that is the subject of the present invention, and having a conductivity measured at 25 ° C of 300 μS cm-1 The aqueous phase (A1) characterized as above may be prepared by mixing natural mineral water, natural water, seawater or algae water with demineralized water to adjust the selected conductivity.

[0036] For the purposes of this invention, the term "natural mineral water" means water in which the content of trace elements is stable, which is suitable for consumption, and whose "total mineralization" meets the requirements of the definition in Article 1322, paragraph 2 of the French Public Health Code, or more generally, meets the provisions of Articles L.1322-1 to L.1322-13, R.1322-1 to R.1322-44-8, and R.1322-45 to R.1322-67 of the French Public Health Code.

[0037] For the purposes of the present invention, "natural mineral water" means a natural mineral water as defined above, used for therapeutic purposes and having received prior authorization from the French prefectural authorities after a directive from the local health authority.

[0038] Examples of natural or mineral waters that can be combined with the aqueous phase (A1) present in the composition (C1) according to the invention are Avens water, Vittel, Witch basin water, Woolridge water, Roche-Posay water, Bourbourg water, Enghien-les-Bains water, Saint-Gervais-les-Bains water, Néris-les-Bains water, Albard-les-Bains water, Digne water, Maisiere water, Neyrac-les-Bains water, Lons-les-Sonia water, Rochefort water, Saint-Christo water, Humades water, Tahsis-les-Bains water, Bagneret-de-Bigolès water, Eugène-les-Bains water, Charles-le-Haut water, Volvic water, Vals water, These include Verney, Aix-les-Bains, Areto, Abatile, Arsene, Arby, Asperjoc, Badois, Silao, Contrex, Evian, Epar, Jouvance, Montlucas, Houju, Oletza, Palo, Perrier, Plancoet, Quezac, Rosana, St. Alban, St. Iamand-les-Hauts, Saint-Georges, Saint-Igueron, Saint-Marguerite, Saint-Illeol, Salveta, Tessieres-les-Bries, Thonon, Treignac, Courmayeur, San Benedetto, and San Pellegrino.

[0039] For purposes of the present invention, the term "algal water" refers to water collected by evaporation and condensation of water contained in harvested algae, said water being derived from the algal cells thus treated. According to specific embodiments, it is water derived from brown algae, red algae, or green algae. According to even more specific embodiments, it is water derived from Laminaria digitata, Chondrus crispus, or Gigartina stellata.

[0040] Examples of algae waters that can be combined with the aqueous phase (A1) present in the composition (C1) according to the invention include Hydralixir TM LD or Hydralixir TM An example is algae water sold under the trade name CC.

[0041] For the purposes of the present invention, the term "galactomannan (GM)" refers to a polysaccharide consisting solely of monosaccharides (or polysaccharides), that is, a polymer whose backbone consists of D-mannose units linked by β-1,4 bonds and to which D-galactose units are grafted along the sides via α-1,6 bonds.

[0042] Polysaccharides are sugar polymers. The IUPAC definition of saccharide refers to monosaccharides, compounds of the monosaccharide itself and their derivatives, obtained by reduction of a carbonyl group, or oxidation of one or more hydroxyl groups, or replacement of one or more hydroxyl groups with hydrogen atoms, amine groups, phosphate groups, or sulfate groups.

[0043] The polysaccharides most commonly used to prepare food, cosmetic, or pharmaceutical compositions consist primarily of monosaccharides such as glucose, galactose, and mannose, or monosaccharide derivatives in which the terminal hydroxyl groups have been oxidized to carboxyl groups. As a result, there are two distinct groups of polysaccharides: those consisting only of monosaccharides (or polymonosaccharides) and those consisting of monosaccharide derivatives. Among the polysaccharides consisting only of monosaccharides, the following can be distinguished: Glucan, a glucose homopolymer that is extremely abundant in nature, Glucomannoglycans, xyloglycans, Galactomannan, a polymer whose main chain consists of D-mannose units linked by β-1,4 bonds and to which D-galactose units are grafted along the sides by α-1,6 bonds.

[0044] Galactomannans are found in several plant species, particularly legumes, which make up the albumen of their seeds.

[0045] Depending on the botanical origin of the galactomannan source, the degree of substitution (DS) of D-galactose units on the D-mannose backbone ranges from 0 to 1: Galactomannans derived from cassia gum have a degree of substitution (DS) of approximately 1 / 5, which means that for every five D-mannose units present on the polysaccharide backbone, one D-galactose unit is grafted along the side; Galactomannans derived from locust bean gum have a degree of substitution (DS) of approximately 1 / 4, which means that for every four D-mannose units present on the polysaccharide backbone, one D-galactose unit is grafted along the side; Galactomannans derived from tara gum have a degree of substitution (DS) of approximately 1 / 3, which means that for every three D-mannose units present on the polysaccharide backbone, one D-galactose unit is grafted along the side; Galactomannans derived from guar gum have a degree of substitution (DS) of approximately 1 / 2, which means that for every two D-mannose units present on the polysaccharide backbone, one D-galactose unit is grafted along the side; Galactomannans derived from fenagle gum have a degree of substitution (DS) of approximately 1 / 1, which means that virtually every D-mannose unit present on the polysaccharide backbone has one D-galactose unit grafted along the side.

[0046] Thus, in the compositions of the present invention, the galactomannan (GM) is selected from the group consisting of galactomannans with a degree of substitution (DS) of about 1 / 3, galactomannans with a degree of substitution (DS) of about 1 / 2, and galactomannans with a degree of substitution (DS) of about 1 / 4.

[0047] In the definition of the composition for topical use (C1) that is the subject of the present invention, the term "crosslinked anionic polyelectrolyte (P1)" means a non-linear crosslinked anionic polyelectrolyte, which is in the form of a three-dimensional network that is insoluble in water but swellable in water, resulting in the formation of a chemical gel.

[0048] In some cases, the compositions of the present invention may have one or more of the following characteristics: - per 100% by weight of the composition, 93 to 99.4% by weight, preferably 95 to 99.3% by weight, more preferably 95.5 to 99.0% by weight, even more preferably 95.5 to 99.0% by weight of the composition has a conductivity of 300 microsiemens / cm (or μS·cm) measured at 25°C -1 ) or more, 0.5 to 5% by mass, preferably 0.5 to 3% by mass, and even more preferably 0.5 to 2.5% by mass of a crosslinked anionic polyelectrolyte (P1), and 0.1 to 2% by mass, preferably 0.2 to 2% by mass, and even more preferably 0.5 to 2% by mass of a galactomannan (GM); - The degree of substitution of the galactomannan is 1 / 3; - the crosslinked anionic polyelectrolyte (P1) comprises monomer units derived from 2-methyl-2[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid in free acid or partially or totally salified form. For the purposes of the present invention, the term "salinated" means that the acid groups present in the monomer are converted to cations, in particular alkali metal salts (for example sodium or potassium ions), nitrogen bases (for example ammonium salts, lysine salts or monoethanolamine salts (HOCH2-CH2-NH3 + )) in the form of an anion bonded to a cation in the form of a salt, such as, for example, sodium or ammonium salts; - the crosslinked anionic polyelectrolyte (P1) is composed of monomer units derived from at least one monomer selected from the group consisting of acrylic acid, methacrylic acid, 2-carboxyethylacrylic acid, itaconic acid, maleic acid and 3-methyl-3-[(1-oxo-2-propenyl)amino]butanoic acid, the carboxyl groups of which are in the free acid or partially or totally salified form; and at least one monomer unit derived from a polyethylenic crosslinking monomer (AR); - the crosslinked anionic polyelectrolyte (P1) consists of monomer units derived from acrylic acid and at least one monomer unit derived from a polyethylenic crosslinking monomer (AR); the polyethylenic crosslinking monomer (AR) is selected from the group consisting of methylenebis(acrylamide), ethylene glycol dimethacrylate, diethylene glycol diacrylate, ethylene glycol diacrylate, diallyl urea, triallylamine, trimethylolpropane triacrylate, diallyloxyacetic acid or a salt thereof such as sodium diallyloxyacetate, or a mixture of these compounds; - the polyethylenic crosslinking monomer (AR) is triallylamine, trimethylolpropane triacrylate or methylenebis(acrylamide), or a mixture of these compounds; - the crosslinked anionic polyelectrolyte (P1) is a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ), partially or totally salified in the form of its sodium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), and acrylic acid (δ), partially or totally salified in the form of its sodium salt, the molar ratio (γ) / (δ) being greater than or equal to 40 / 60 and less than or equal to 90 / 10; a copolymer of 2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) and hydroxyethyl acrylate (ζ) in which the molar ratio (γ) / (ζ) is 30 / 70 or more and 90 / 10 or less; a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or completely salified in the form of a sodium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), and acrylamide (ε) in which the molar ratio (γ) / (ε) is 30 / 70 or more and 90 / 10 or less. The mass ratio of galactomannan (GM) to crosslinked anionic polyelectrolyte (P1) is 0.15 to 0.75, preferably 0.20 to 0.60, more preferably 0.25 to 0.60, and even more preferably 0.20 to 0.50.

[0049] According to a particular embodiment, the crosslinked anionic polyelectrolyte (P1) comprises, per 100 mol %, (a1) - a proportion of 25 to 100 mol % of monomer units derived from 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid in free acid or partially or completely salified form; (a2) - optionally containing more than 0 mol % to 75 mol % of monomer units derived from at least one monomer selected from the group consisting of acrylamide, N,N-dimethylacrylamide; methacrylamide; tert-butylacrylamide, and N-isopropylacrylamide; Percentage below 100%; (a3) - optionally, more than 0 mol% and up to 20 mol%, preferably more than 0 mol% and up to 15 mol%, more preferably more than 0 mol% and up to 10 mol% of monomer units derived from at least one monomer selected from the group consisting of (2-hydroxyethyl)acrylate, (2,3-dihydroxypropyl)acrylate, (2-hydroxyethyl)methacrylate, (2,3-dihydroxypropyl)methacrylate and vinylpyrrolidone; (a4) - optionally, a proportion of more than 0 mol % and up to 75 mol % of monomer units derived from at least one monomer selected from the group consisting of acrylic acid, methacrylic acid, 2-carboxyethylacrylic acid, itaconic acid, maleic acid and 3-methyl-3-[(1-oxo-2-propenyl)amino]butanoic acid, in which the carboxy group is in the free acid or partially or completely salified form; (a5) - optionally at least one monomer of formula (I) in a proportion of more than 0 mol % and up to 5 mol %: [ka] In the formula, R represents a linear or branched alkyl group containing 8 to 20 carbon atoms, and n represents an integer of 0 or more and 20 or less. (a6) - a proportion of monomer units derived from at least one polyethylene crosslinking monomer (AR) greater than 0 mol% and less than or equal to 1 mol%; The sum of said molar proportions of the monomer units a1), a2), a3), a4), a5) and a6) is equal to 100 mol %.

[0050] According to another particular aspect of the invention, the composition (C1) for topical use is characterized in that said polyethylenic crosslinking monomer (AR) as defined above is used in a molar ratio of less than or equal to 0.5% by mole, more preferably less than or equal to 0.25% by mole and most preferably less than or equal to 0.1% by mole; more preferably, the molar ratio is greater than or equal to 0.005% by mole.

[0051] The crosslinked anionic polyelectrolytes (P1) used in the compositions for topical use (C1) that are the subject of the present invention may also contain various additives such as complexing agents, transport agents or chain limiters.

[0052] The crosslinked anionic polyelectrolytes (P1) used in the compositions for topical use (C1) that are the subject of the present invention may also contain various additives such as complexing agents, transport agents or chain limiters.

[0053] The crosslinked anionic polyelectrolytes (P1) used in the composition for topical use (C1) that is the subject of the present invention can be prepared by radical polymerization methods known to those skilled in the art, such as solution polymerization, suspension polymerization, inverse suspension polymerization, emulsion polymerization, inverse emulsion polymerization or polymerization in a solvent, followed by a precipitation step of the polymer formed.

[0054] According to a more specific embodiment, the crosslinked anionic polyelectrolytes (P1) used in the composition for topical use (C1) that is the subject of the present invention can be prepared by carrying out a polymerization step in a solvent followed by a step of precipitation of the polymer formed, or by carrying out an inverse emulsion polymerization step, optionally followed by a step of concentration and / or atomization.

[0055] According to a more specific embodiment, the crosslinked anionic polyelectrolyte (P1) used in the topical composition (C1) of the present invention can be prepared according to one of the methods described above and may include the use of a chain transfer agent or chain limiter. The chain transfer agent or chain limiter is more specifically selected from the group consisting of sodium hypophosphite, low molecular weight alcohols (e.g., methanol, ethanol, 1-propanol, isopropanol, or butanol), thiols (e.g., 2-mercaptoethanol), transfer agents containing sulfate groups (e.g., sodium methallylsulfonate), or mixtures of such transfer agents. The chain transfer agent or chain limiter is more specifically used in a molar ratio of 0.001 to 1 mol %, more preferably 0.001 to 0.5 mol %, and most preferably 0.001 to 0.1 mol %, based on the total number of moles of monomers used.

[0056] According to another particular embodiment of the invention, the crosslinked anionic polyelectrolyte (P1) is selected from the group consisting of: acrylic acid homopolymers partially or totally salified in the form of their sodium or ammonium salts, crosslinked with triallylamine and / or methylenebis(acrylamide); 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid homopolymers partially or totally salified in the form of their sodium or ammonium salts, crosslinked with triallylamine and / or methylenebis(acrylamide); copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid partially or totally salified in the form of its sodium or ammonium salts, crosslinked with triallylamine and / or methylenebis(acrylamide); copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid partially or totally salified in the form of its sodium or ammonium salts, crosslinked with triallylamine and / or methylenebis(acrylamide); copolymers of acrylic acid partially or totally salified in the form of its sodium or ammonium salts, crosslinked with triallylamine and / or methylenebis(acrylamide). copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) crosslinked with acrylic acid (δ) partially or totally salified in the form of its sodium salt, the molar ratio (γ) / (δ) being between 30 / 70 and 90 / 10; copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or totally salified in the form of its sodium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), and acrylic acid (δ) partially or totally salified in the form of its sodium salt, the molar ratio (γ) / (δ) being between 30 / 70 and 90 / 10; copolymers of acrylic acid (δ) partially or totally salified in the form of its sodium salt, with a molar ratio (γ) / (δ) of 40 / 60 or more and 90 / 10 or less; copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or totally salified in the form of its sodium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), with acrylamide (ε), with a molar ratio (γ) / (ε) of 30 / 70 or more and 90 / 10 or less;Copolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ), partially or totally salified in the form of its sodium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), and hydroxyethyl acrylate (ζ), in which the molar ratio (γ) / (ζ) is 30 / 70 or more and 90 / 10 or less; 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, partially or totally salified in the form of its sodium salt or ammonium salt, crosslinked with triallylamine and / or methylenebis(acrylamide). terpolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, partially or totally salified in the form of its sodium or ammonium salt, in a molar ratio of 30% to 45%, crosslinked with triallylamine and / or methylenebis(acrylamide), in a molar ratio of 45% to 68%, acrylamide, and in a molar ratio of 2% to 10%, crosslinked with triallylamine and / or methylenebis(acrylamide); terpolymers of 30% to 45% by mole of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, partially or totally salified in the form of its sodium or ammonium salt, crosslinked with triallylamine and / or methylenebis(acrylamide), 47% to 68% by mole of acrylamide, and 2% to 8% by mole of acrylic acid, partially or totally salified in the form of its sodium or ammonium salt; terpolymers of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, partially or totally salified in the form of its sodium or ammonium salt, crosslinked with trimethylolpropane triacrylate and / or triallylamine and / or methylenebis(acrylamide), terpolymers of 60% to 80% of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid, partially or fully salified in the form of its sodium or ammonium salt, crosslinked with trimethylolpropane triacrylate and / or triallylamine and / or methylenebis(acrylamide), in a molar ratio of 15% to 39.5%, and in a molar ratio of 0.5% to 2.5%, and in a molar ratio of 0.5% to 2.5%, of stearoyl methacrylate.

[0057] The subject of the present invention is also a formulation (F) for topical use, a composition for topical use (C1) as defined above; and - a fatty phase (A2) comprising i) at least one oil and ii) an emulsifying system comprising at least one emulsifier (S1), Includes.

[0058] Preferably, the composition according to the invention comprises, per 100% by weight: - 60 to 90% by weight of composition (C1); and - 10-40% by mass of fatty phase (A2), include.

[0059] The emulsifier (S1) may be selected from the group consisting of alkyl polyglycoside compositions, compositions of alkyl polyglycosides and fatty alcohols, polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

[0060] In the formulations for topical use (F) that are the subject of the present invention, the term "oil" means water-insoluble compounds and / or mixtures of compounds that are liquid at 25°C, more particularly: - linear alkanes containing 11 to 19 carbon atoms; - Branched alkanes containing 7 to 40 carbon atoms, such as isododecane, isopentadecane, isohexadecane, isoheptadecane, isooctadecane, isononadecane or isoeicosane, or C 7-8 Isoparaffin, C 8-9 Isoparaffin, C 9-11 Isoparaffin, C 9-12 Isoparaffin, C 9-13 Isoparaffin, C 9-14 Isoparaffin, C 9-16 Isoparaffin, C 10-11 Isoparaffin, C 10-12 Isoparaffin, C 10-13 Isoparaffin, C 11-12 Isoparaffin, C 11-13 Isoparaffin, C 11-14 Isoparaffin, C 12-14 Isoparaffin, C 12-20 Isoparaffin, C 13-14 Isoparaffin, C 13-16 Mixtures of those identified by their INCI names, such as isoparaffins; - cycloalkanes optionally substituted with one or more linear or branched alkyl groups; - Marcol TM 52. Marcol TM 82, Drakeol TM 6VR, Eolane TM 130, Eolane TM White mineral oil, such as products sold under the trade name 150; - hemisqualane (or 2,6,10-trimethyldodecane; CAS number: 3891-98-3), squalane (or 2,6,10,15,19,23-hexamethyltetracosane), hydrogenated polyisobutene or hydrogenated polydecene; - A mixture of alkanes containing 15 to 19 carbon atoms, wherein the alkanes are linear alkanes, branched alkanes, and cycloalkanes. More specifically, a mixture (M1) containing, per 100 mass%, 90 mass% to 100 mass% of branched alkanes; 0 mass% to 9 mass%, more preferably less than 5%, of linear alkanes; and 0 mass% to 1 mass% of cycloalkanes. For example, the mixture can be prepared by Emogreen TM L15 or Emogreen TM It is sold under the trade name L19. fatty alcohol ethers of formula (II): Z1-O-Z2(II) In formula (II), Z1 and Z2 may be the same or different and represent a linear or branched alkyl group containing 5 to 18 carbon atoms, such as dioctyl ether, didecyl ether, didodecyl ether, dodecyl octyl ether, dihexadecyl ether, (1,3-dimethylbutyl)tetradecyl ether, (1,3-dimethylbutyl)hexadecyl ether, bis(1,3-dimethylbutyl)ether or dihexyl ether; monoesters of fatty acids and alcohols of formula (III): R'1-(C=O)-O-R'2(III) In formula (III), R'1-(C=O) represents a saturated or unsaturated, straight-chain or branched acyl group containing 8 to 24 carbon atoms, and R'2, independently of R'1, represents a saturated or unsaturated, straight-chain or branched hydrocarbon chain containing 1 to 24 carbon atoms, such as methyl laurate, ethyl laurate, propyl laurate, isopropyl laurate, butyl laurate, 2-butyl laurate, hexyl laurate, methyl cocoate, ethyl cocoate, propyl cocoate, isopropyl cocoate, butyl cocoate, 2-butyl cocoate, hexyl cocoate, methyl myristate, ethyl myristate, propyl myristate, isopropyl myristate, butyl myristate, 2-butyl myristate, hexyl myristate, octyl myristate, methyl palmitate, methyl oleate, ethyl palmitate, propyl palmitate, isopropyl palmitate, butyl palmitate, 2-butyl palmitate, hexyl palmitate, octyl palmitate, methyl oleate, ethyl oleate, propyl oleate, isopropyl oleate, butyl oleate, 2-butyl oleate, hexyl oleate, octyl oleate, methyl stearate, ethyl stearate, propyl stearate, isopropyl stearate, butyl stearate, 2-butyl stearate, hexyl stearate, octyl stearate, methyl isostearate, ethyl isostearate, propyl isostearate, isopropyl isostearate, butyl isostearate, 2-butyl isostearate, hexyl isostearate, and isostearyl isostearate. diesters of fatty acids and glycerol of formula (IV) and formula (V): R'3-(C=O)-O-CH2-CH(OH)-CH2-O-(C=O)-R'4 (IV) R'5-(C=O)-O-CH2-CH[O-(C=O)-R'6]-CH2-OH (V) In formulas (IV) and (V), R'3-(C=O), R'4-(C=O), R'5-(C=O) and R'6-(C=O) may be the same or different and represent a saturated or unsaturated, straight-chain or branched-chain acyl group containing 8 to 24 atoms; triesters of fatty acids and glycerol of formula (VI): R'7-(C=O)-O-CH2-CH[O-(C=O)-R'8]-CH2-O-(C=O)-R'9(VI) In formula (VI), R'7-(C=O), R'8-(C=O) and R'9-(C=O) may be the same or different and represent a saturated or unsaturated, straight-chain or branched-chain acyl group containing 8 to 24 atoms; - vegetable oils such as phytosqualane, sweet almond oil, coconut kernel oil, castor oil, jojoba oil, olive oil, rapeseed oil, peanut oil, sunflower oil, wheat germ oil, corn germ oil, soybean oil, cottonseed oil, alfalfa seed oil, poppy seed oil, pumpkin seed oil, sardine oil, barley oil, rye oil, safflower oil, candlenut oil, passion flower oil, hazelnut oil, palm oil, shea butter, apricot kernel oil, cocamidopropyl betaine oil, cymbopogon oil, avocado oil, and oils of flower or vegetable origin; - Ethoxylated vegetable oil Examples include:

[0061] Preferably, the composition according to the invention comprises at least one oil selected from the group consisting of castor oil, liquid paraffin, cocoyl caprate / caprylate, isopropyl myristate and capric / caprylic triglyceride.

[0062] The fatty phase (A2) optionally comprises a wax. In the formulations for topical use (F) that are the subject of the present invention, the term "wax" means a water-insoluble compound and / or mixture of compounds that is solid at 35°C.

[0063] More specifically, such waxes are selected from beeswax, carnauba wax, candelilla wax, olicury wax, Japan wax, cork fiber wax, sugarcane wax, paraffin wax, lignite wax, microcrystalline wax, lanolin wax; ozokerite; polyethylene wax; silicone wax; vegetable waxes; fatty alcohols and fatty acids that are solid at room temperature; and glycerides that are solid at room temperature.

[0064] In the formulation (F) that is the subject of the present invention, the term "alkyl polyglycoside composition" means a composition (C2) of formula (VII): R1-O-(G) x -H (VII) In the formula, x represents a decimal number between 1.05 and 5, G represents a reducing sugar residue, and R 1 represents a saturated or unsaturated, linear or branched aliphatic hydrocarbon group containing 12 to 36 carbon atoms, optionally substituted with one or more hydroxy groups, and the composition (C2) consists of a mixture of compounds represented by formulae (VII1), (VII2), (VII3), (VII4) and (VII5): R1-O-(G)1-H (VII1) R1-O-(G)2-H (VII2) R1-O-(G)3-H (VII3) R1-O-(G)4-H (VII4) R1-O-(G)5-H (VII5) If the respective molar ratios are a1, a2, a3, a4 and a5, then - the sum of a1+a2+a3+a4+a5 is equal to 1, - The sum of a1+2a2+3a3+4a4+5a5 is equal to x.

[0065] The term "a saturated or unsaturated, straight or branched chain aliphatic hydrocarbon group containing 12 to 36 carbon atoms, optionally substituted with one or more hydroxy groups" means the group R1 of formula (VII) as defined above: saturated linear alkyl groups such as n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl, n-eicosyl and n-docosyl; - unsaturated linear groups such as dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nonadecenyl, eicosenyl, docosenyl, 4-dodecenyl and 5-dodecenyl; saturated or unsaturated, linear or branched aliphatic groups containing 12 to 36 carbon atoms substituted by one or two hydroxy groups, such as hydroxydodecyl, hydroxytetradecyl, hydroxyhexadecyl, hydroxyoctadecyl, hydroxyeicosyl and hydroxydocosyl groups, for example 12-hydroxyoctadecyl; a group derived from an isoalkanol of formula (1): (CH3)(CH3)CH-(CH2) r -(CH2)-OH (1) In the formula, r is an integer of 8 to 20, and represents, for example, an isodecyl group, an isoundecyl group, an isododecyl group, an isotridecyl group, an isotetradecyl group, an isopentadecyl group, an isohexadecyl group, an isopentadecyl group, an isooctadecyl group, an isononadecyl group, an isoeicosyl group, or an isodocosyl group; Branched alkyl groups derived from Guerbet alcohols of formula (2): CH(C s H 2s+1 )(C t H 2t+1 )-(CH2)-OH (2) In the formula, t is an integer of 6 to 18, s is an integer of 4 to 18, and s+t is 10 or more and 22 or less, and examples thereof include a 2-butyloctyl group, a 2-butyldecyl group, a 2-hexyloctyl group, a 2-hexyldecyl group, a 2-octyldecyl group, a 2-hexyldodecyl group, a 2-octyldodecyl group, a 2-decyltetradecyl group, a 2-dodecylhexadecyl group, and a 2-tetradecyloctadecyl group.

[0066] According to a particular embodiment, in the definition of formula (VII) defined above, R1 represents a saturated or unsaturated, linear or branched aliphatic hydrocarbon group containing from 12 to 24 carbon atoms.

[0067] The term "reducing sugar" in the definition of formula (VII) defined above means a sugar derivative that does not have a glycosidic bond established in its structure between the anomeric carbon and the oxygen of the acetal group, as defined in the reference: "Biochemistry, Daniel Voet / Judith GVoet, page 250, John Wiley & Sons, 1990". Oligomeric structure (G) x may be any isomeric form, whether optical, geometric or positional isomer, or may be a mixture of isomers.

[0068] In the above formula (VII), the R1-O- group is attached to G through the anomeric carbon of the sugar residue to form an acetal group.

[0069] According to a particular embodiment in the definition of formula (VII) defined above, G represents a reducing sugar residue selected from glucose, dextrose, sucrose, fructose, idose, gulose, galactose, maltose, isomaltose, maltotriose, lactose, cellobiose, mannose, ribose, xylose, arabinose, lyxose, allose, altrose, dextran and talose, more preferably G represents a reducing sugar residue selected from glucose, xylose and arabinose residues.

[0070] According to an even more specific embodiment, in the definition of formula (VII) representing composition (C2) contained in composition (F) that is the subject of the present invention, x is a decimal value greater than or equal to 1.05 and less than or equal to 2.5, more specifically greater than or equal to 1.05 and less than or equal to 2.0, and even more specifically greater than or equal to 1.25 and less than or equal to 2.0. represent.

[0071] According to an even more specific embodiment, in the definition of formula (VII) defined above, R1 represents a group selected from at least one of the group consisting of n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl, n-docosyl, 2-hexyldecyl, 2-octyldecyl, 2-hexyldodecyl, 2-octyldodecyl, and 2-decyltetradecyl, G represents a reducing sugar residue selected from glucose and xylose residues, and x represents a decimal number between 1.05 and 2.5.

[0072] According to an even more specific embodiment, the formulation (F) as defined above is characterized in that said emulsifying system consists of an alkyl polyglycoside composition (C2) of formula (VII): R1-O-(G) x -H (VII) In the formula, x represents a decimal number between 1.05 and 5, G represents a xylose residue, and R 1 represents a 2-octyldodecyl group, and said composition (C2) consists of a mixture of compounds represented by formulas (VII1), (VII2), (VII3), (VII4) and (VII5): R1-O-(G)1-H (VII1) R1-O-(G)2-H (VII2) R1-O-(G)3-H (VII3) R1-O-(G)4-H (VII4) R1-O-(G)5-H (VII5) If the respective molar ratios are a1, a2, a3, a4 and a5, then - the sum of a1+a2+a3+a4+a5 is equal to 1, - The sum of a1+2a2+3a3+4a4+5a5 is equal to x.

[0073] In the description of the formulation (F) that is the subject of the present invention, the term "alkyl polyglycoside and fatty alcohol composition" means, per 100% by weight thereof: - 10 to 50% by weight, preferably 15 to 40% by weight, more preferably 20 to 30% by weight of at least one composition (C2) of formula (VII) as defined above, - 90 to 50% by weight, preferably 85 to 60% by weight, more preferably 80 to 70% by weight of at least one fatty alcohol of formula (VIII): means a composition (C3) comprising: R'1-OH (VIII) In the formula, R'1 may be the same as or different from R1 and represents a saturated or unsaturated, straight-chain or branched-chain aliphatic hydrocarbon group containing 12 to 36 carbon atoms, which may be substituted with one or more hydroxy groups.

[0074] According to a particular embodiment, in the definition of formula (VII) representing composition (C2) contained in composition (C3), R1 represents a group selected from n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl, n-docosyl, 2-hexyldecyl, 2-octyldecyl, 2-hexyldodecyl, 2-octyldodecyl, and 2-decyltetradecyl, G represents a reducing sugar residue selected from glucose and xylose residues, and x represents a decimal number between 1.05 and 2.5.

[0075] According to a more specific embodiment, in the definition of formula (VII) representing composition (C2) contained in composition (C3), R1 represents a 2-octyldodecyl group, G represents a xylose residue, and x represents a decimal number of 1.05 or more and 2.5 or less.

[0076] According to a more specific embodiment, in the definition of the fatty alcohol of formula (VIII) defined above, R'1 is n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl, n-docosyl, 2-hexyldecyl, 2-octyl It represents a group selected from decyl, 2-hexyldodecyl, 2-octyldodecyl and 2-decyltetradecyl groups, and most preferably R'1 is a 2-octyldodecyl group.

[0077] According to an even more particular aspect, the subject of the invention is formulation (F) as defined above, characterized in that said emulsifying system consists of composition (C3), which comprises, per 100% by weight of composition (C3), the following components: - 10 to 50% by weight of at least one alkyl polyglycoside composition (C2) of formula (VII): R1-O-(G) x -H (VII) wherein x represents a decimal number between 1.05 and 2.5, G represents a xylose residue, R1 represents a 2-octyldodecyl group, and the composition consists of a mixture of compounds represented by formulas (VII1), (VII2), (VII3), (VII4) and (VII5): R1-O-(G)1-H (VII1) R1-O-(G)2-H (VII2) R1-O-(G)3-H (VII3) R1-O-(G)4-H (VII4) R1-O-(G)5-H (VII5) If the respective molar ratios are a1, a2, a3, a4 and a5, then The sum of a1+a2+a3+a4+a5 is equal to 1, The sum of a1+2a2+3a3+4a4+5a5 is equal to x, - 90 to 50% by weight of at least one fatty alcohol of formula (VIII): R'1-OH (VIII) In the formula, R'1 represents a 2-octyldodecyl group.

[0078] In the definition of formulation (F) that is the subject of the present invention, the term "polyglycerol ester" means a compound of formula (IX): [ka] In the formula, Z represents an acyl group of the formula R2-C(=O)-, where R2 represents a saturated or unsaturated, linear or branched aliphatic hydrocarbon group containing 11 to 35 carbon atoms, more specifically a group selected from dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl, eicosanoyl, docosanoyl, oleyl, linoleyl, linolenoyl, and isostearyl. Z' represents an acyl group of the formula R2-C(=O)- as defined above, where Z' may be the same as or different from Z or represents a hydrogen atom, and y represents an integer of 2 to 20.

[0079] According to a more particular embodiment, the compound of formula (IX) is selected from the group consisting of decaglyceryl oleate, decaglyceryl isostearate, decaglyceryl monolaurate, decaglyceryl monolinoleate and decaglyceryl monomyristate.

[0080] In the definition of the formulation (F) that is the subject of the present invention, the term "alkoxylated polyglycerol ester" means a compound of formula (X): [ka] Here, Z1 represents an acyl group of the formula R'2-C(=O)-, where R'2 represents a saturated or unsaturated, linear or branched aliphatic hydrocarbon group containing 11 to 35 carbon atoms, more specifically, a group selected from dodecanoyl, tetradecanoyl, hexadecanoyl, octadecanoyl, eicosanoyl, docosanoyl, oleyl, linoleyl, linolenoyl, and isostearyl. Z1' represents an acyl group of the formula R'2-C(=O)- as defined above, which may be the same as or different from Z1, or represents a hydrogen atom. R3 represents a hydrogen atom, a methyl group, or an ethyl group. y1 represents an integer of 2 or more and 20 or less, v1, v2, and v3 may be the same or different and represent an integer of 0 or more and 50 or less, and the sum [(y1·v1)+(y1·v2)+v3] represents an integer of 1 or more and 50 or less.

[0081] In the definition of the formulation (F) that is the subject of the present invention, the term "polyglycol polyhydroxystearate" means a compound of formula (XI): [ka] In the formula, y2 represents an integer of 2 or more and 50 or less, R4 represents a hydrogen atom, a methyl group, or an ethyl group, and Z2 represents a group of formula (XII): [ka] In the formula, y'2 represents an integer of 0 or more and 10 or less, more preferably 1 or more and 10 or less, and Z'2 represents a group of formula (XII) defined above, which may be the same as or different from Z2, or represents a hydrogen atom.

[0082] In the definition of formulation (F) that is the subject of the present invention, the term "polyglycerol polyhydroxystearate" means a compound of formula (XIII): [ka] wherein Z3 represents a group of formula (XII) as defined above, and Z'3 represents a group of formula (XII) as defined above. (XII) and may be the same as or different from Z3, or may represent a hydrogen atom. y3 represents an integer of 2 or more and 20 or less.

[0083] In the definition of formulation (F) that is the subject of the present invention, the term "alkoxylated polyglycerol polyhydroxystearate" means a compound of formula (XIV): [ka] In the formula, Z4 represents a group of formula (XII) defined above, Z'4 represents a group of formula (XII) defined above, and Z'4 may be the same as or different from Z4 or represent a hydrogen atom. y4 represents an integer of 2 or greater and 20 or less, and v'1, v'2, and v'3 may be the same as or different from each other and represent an integer of 0 or greater and 50 or less. The sum [(y4·v'1)+(y4·v'2)+v'3] is an integer of 1 or greater and 50 or less.

[0084] According to another particular aspect, the subject of the invention is a formulation (F) as defined above, characterized in that said emulsifying system (S) consists of a composition (C4): Composition (C4) contains the following components per 100 mass %. 15 to 25% by weight of at least one composition (C2) represented by formula (VII): R1-O-(G) x -H (VII) In the formula, x represents a decimal number of 1.05 to 2.5, G represents a xylose residue, R1 represents a 2-octyldodecyl group, and the composition (C2) consists of a mixture of compounds represented by formulas (VII1), (VII2), (VII3), (VII4) and (VII5): R1-O-(G)1-H (VII1) R1-O-(G)2-H (VII2) R1-O-(G)3-H (VII3) R1-O-(G)4-H (VII4) R1-O-(G)5-H (VII5) If the respective molar ratios are a1, a2, a3, a4 and a5, then - the sum of a1+a2+a3+a4+a5 is equal to 1, - The sum of a1+2a2+3a3+4a4+5a5 is equal to x, 55 to 65% by weight of at least one fatty alcohol of formula (VIII): R'1-OH (VIII) In the formula, R'1 represents a 2-octyldodecyl group; 10 to 30% by mass of at least one polyglycol polyhydroxystearate represented by formula (XI): [ka] In the formula, y2 represents an integer of 2 or more and 50 or less, R4 represents a hydrogen atom, a methyl group, or an ethyl group, and Z2 represents a group of formula (XII): [ka] In the formula, y'2 represents an integer of 0 or more and 10 or less, more preferably 1 or more and 10 or less, and Z'2 represents a group of formula (XII) defined above, which may be the same as or different from Z2, or is a hydrogen atom.

[0085] According to another particular aspect, the subject of the invention is formulation (F) as defined above, characterized in that it has a dynamic viscosity of 500 mPa·s to 40,000 mPa·s, measured at a temperature of 25°C using a Brookfield LVT viscometer at a speed of 6 rpm.

[0086] A subject of the present invention is also a composition (C1) according to the invention that can be administered topically to cleanse and / or protect and / or care for the skin, hair, scalp, nails, lips, eyelashes or eyebrows of the human or animal body.

[0087] Likewise, a subject of the present invention is also a formulation (F) according to the invention that can be administered topically to cleanse and / or protect and / or care for the skin, hair, scalp, nails, lips, eyelashes or eyebrows of the human or animal body.

[0088] The composition for topical use (C1) and the formulation for topical use (F) defined above can be applied to human skin using a finger or an applicator, such as a brush, sponge or wipe pre-impregnated with said composition for topical use (C1) and the formulation for topical use (F) defined above.

[0089] The compositions (C1) and formulations (F) for topical use that are the subject of the present invention may be packaged in pressurized form in aerosol devices or "pump bottle" type devices, devices with perforated walls, such as grills, or devices with ball applicators (known as "roll-ons").

[0090] The compositions (C1) and preparations (F) for topical use that are the subject of the present invention can be used as cleansing or makeup-removing milks, as cleansing or makeup-removing lotions, as foaming gels for the face or body, as shampoos for washing the hair and / or scalp, as hair conditioners for treating the hair and / or scalp, as bubble baths, as creams, as milks or as lotions for caring for or protecting the face, hands and body, for example as sunscreens, self-sunscreens, anti-aging agents, anti-wrinkle agents, soothing agents or moisturizers.

[0091] The compositions (C1) and formulations (F) for topical use that are the subject of the present invention may also comprise excipients and / or active ingredients that are commonly used in formulations for topical use, in particular in the field of cosmetic, dermocosmetic, pharmaceutical or dermopharmaceutical formulations.

[0092] According to another particular aspect, the subject of the present invention is a composition comprising foaming and / or detergent surfactants, thickening and / or gelling surfactants, stabilizers, film-forming compounds, solvents and cosolvents, hydrotropic agents, plasticizers, emulsifiers and coemulsifiers, opacifiers, brighteners, superfatting agents, metal ions, Compositions (C1) and formulations (F) for topical use as defined above, characterized in that they also contain one or more auxiliary compounds chosen from sequestering agents, chelating agents, antioxidants, fragrances, essential oils, preservatives, conditioning agents, deodorizing agents, bleaching agents intended to bleach hair and skin, active ingredients intended to provide a treating and / or protective action on the skin or hair, sunscreens, inorganic fillers or pigments, particles intended to impart visual effects or activators, exfoliants, particles intended to encapsulate texturing agents, optionally optical brighteners and insect repellents.

[0093] Examples of foaming and / or detergent surfactants that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include the topically acceptable anionic, cationic, amphoteric or nonionic foaming and / or detergent surfactants commonly used in this field.

[0094] Foaming and / or detergent anionic surfactants that can be combined with the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include: alkyl ether sulfates, alkyl sulfates, alkylamido ether sulfates, alkylaryl polyether sulfates, monoglyceride sulfates, α-olefin sulfonates, paraffin sulfonates, alkyl phosphates, alkyl ether phosphates, alkyl sulfonates, alkylamido sulfonates, alkylaryl sulfonates, alkyl carboxylates, alkyl sulfosuccinates, alkyl ether sulfosuccinates, alkylamido sulfosuccinates, alkyl sulfoacetates, alkyl sarcosinates, acyl isethionates, N-acyltaurates, acyl lactylates, N-acylamino acid derivatives, N-acyl peptide derivatives, N-acyl protein derivatives, or the alkali metal, alkaline earth metal, ammonium, amine or amino alcohol salts of fatty acids.

[0095] Among the foaming and / or detergent amphoteric surfactants that may be combined with the compositions (C1) and preparations (F) for topical use that are the subject of the present invention, mention may be made of alkylbetaines, alkylamidobetaines, sultaines, alkylamidoalkylsulfobetaines, imidazoline derivatives, phosphobetaines, amphopolyacetates and amphopropionates.

[0096] Among the foaming and / or detergent cationic surfactants that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention, mention may in particular be made of quaternary ammonium derivatives.

[0097] Among the foaming and / or detergent nonionic surfactants that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention, mention may be made of castor oil derivatives, polysorbates, coconut kernel amides and N-alkylamines.

[0098] Examples of thickening and / or gelling surfactants that may be present in the compositions (C1) and preparations (F) for topical use that are the subject of the present invention include: - optionally alkoxylated polyalkylglycoside fatty acid esters, in particular ethoxylated methyl polyglucoside esters, such as PEG-120 methyl glucose trioleate and PEG-120 methyl glucose dioleate, respectively, Glucamate TM LT and Glucamate TM Sold under the trade name DOE120; - Crothix TM PEG-150 Pentaerythrityl Tetrastearate, sold under the trade name DS53, and Anti TM alkoxylated fatty acid esters such as PEG-55 propylene glycol oleate, sold under the trade name 141; - Elfacos TM PPG-14 Laureth Isofloryl Dicarbamate, sold under the trade name T211, or Elfacos TM Sold under the trade name GT2125 Aliphatic polyalkylene glycol carbamates such as PPG-14 Palmeth-60 hexyl dicarbamate.

[0099] Examples of emulsifying surfactants that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include nonionic surfactants, anionic surfactants and cationic surfactants.

[0100] Examples of emulsifying nonionic surfactants that may be present in the compositions (C1) and preparations (F) for topical use that are the subject of the present invention include Montane TM 80, Montane TM 85 and Montane TM Fatty acid esters of sorbitol sold under the trade name Simulsol TM ethoxylated castor oil and ethoxylated hydrogenated castor oil sold under the trade name 989; compositions containing glyceryl stearate and polyethoxylated stearic acid having 5 to 150 moles of ethylene oxide (e.g., Simulsol TM a composition containing (ethoxylated) stearic acid and glyceryl stearate having 135 moles of ethylene oxide, sold under the trade name 165; an ethoxylated sorbitan ester (e.g., Montanox TM products sold under the trade name); mannitan esters; ethoxylated mannitan esters; sucrose esters; and methyl glucoside esters.

[0101] Examples of emulsifying anionic surfactants that may be present in the compositions (C1) and in the preparations (F) for topical use that are the subject of the present invention include decyl phosphate, Amphisol TM Cetyl phosphate, glyceryl stearate citrate; cetearyl sulfate; Sensanov TM These include arachidyl / benzyl phosphate and arachidyl / benzyl alcohol compositions sold under the trade name WR; soaps (e.g., sodium stearate or triethanolammonium stearate), and salified N-acyl derivatives of amino acids (e.g., stearoyl glutamate).

[0102] Examples of emulsifying cationic surfactants that may be present in the compositions (C1) and in the formulations (F) for topical use that are the subject of the present invention include amine oxides, Quaternium-82, surfactants described in WO 96 / 00719, and mainly those whose fatty chains contain at least 16 carbon atoms.

[0103] Examples of opacifiers and / or glazing agents that may be present in the compositions (C1) and in the formulations (F) for topical use that are the subject of the present invention include sodium palmitate, sodium stearate, sodium hydroxystearate, magnesium palmitate, magnesium stearate, magnesium hydroxystearate, ethylene glycol monostearate, ethylene glycol distearate, polyethylene glycol monostearate, polyethylene glycol distearate, and fatty alcohols containing 12 to 22 carbon atoms.

[0104] Examples of texturizing agents that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include N-acylamino acid derivatives (e.g. Aminohydroxybenzoates), TM Lauroyl lysine, sold under the trade name LL, and Sepifine TM Babassu starch, sold under the trade name Dryflo TM Octenyl starch succinate, sold under the trade name Montanov TM Mention may be made of myristyl polyglucosides, which are sold under 14 trade names, cellulose fibers, cotton fibers, chitosan fibers, talc, sericite and mica.

[0105] Examples of solvents and cosolvents that may be present in the compositions (C1) and in the formulations (F) for topical use that are the subject of the present invention are water, organic solvents (such as glycerol, diglycerol, glycerol oligomers, ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, diethylene glycol, xylitol, erythritol, sorbitol, water-soluble alcohols (e.g., ethanol, isopropanol or butanol), mixtures of water and the aforementioned organic solvents, propylene carbonate, ethylene carbonate and benzyl alcohol).

[0106] Examples of agents for improving skin penetration that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include glycol ethers (such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monoisopropyl ether, ethylene glycol monobutyl ether, ethylene glycol monophenyl ether, ethylene glycol monobenzyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether and diethylene glycol mono-n-butyl ether, diethylene glycol monoethyl ether (or Transcutol-P)), fatty acids such as oleic acid, fatty acid esters of glycerol (such as glyceryl behenate, glyceryl palmitostearate, behenoyl macroglyceride, polyoxyethylene-2-stearyl ether, polyoxyethylene-2-oleyl ether, terpenes (such as D-limonene), and essential oils (such as eucalyptus oil).

[0107] Examples of deodorants that may be present in the compositions (C1) and in the preparations (F) for topical use that are the subject of the present invention include alkaline silicates, zinc salts such as zinc sulfate, zinc gluconate, zinc chloride or zinc lactate; quaternary ammonium salts such as cetyltrimethylammonium, cetylpyridinium salts; glycerol derivatives such as glyceryl caprate, glyceryl caprylate and polyglyceryl caprate; 1,2-decanediol, 1,3-propanediol; salicylic acid; sodium bicarbonate; cyclodextrins; metal zeolites; triclosan. TMaluminum bromohydrate, aluminum chlorohydrate, aluminum chloride, aluminum sulfate, aluminum zirconium chlorohydrate, aluminum zirconium trichlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium octachlorohydrate, aluminum sulfate, sodium aluminum lactate, and aluminum chlorohydrate and glycol complexes such as a complex of aluminum chlorohydrate and propylene glycol, a complex of aluminum dichlorohydrate and propylene glycol, a complex of aluminum sesquichlorohydrate and propylene glycol, a complex of aluminum chlorohydrate and polyethylene glycol, a complex of aluminum dichlorohydrate and polyethylene glycol, or a complex of aluminum sesquichlorohydrate and polyethylene glycol.

[0108] Examples of antioxidants that may be present in the compositions (C1) and in the preparations (F) for topical use that are the subject of the present invention include mixtures of antioxidant compounds such as EDTA and its salts, citric acid, tartaric acid, oxalic acid, BHA (butylhydroxyanisole), BHT (butylhydroxytoluene), tocopherol derivatives such as tocopherol acetate, disorbin GL 47S (INCI name: tetrasodium glutamate diacetate).

[0109] The composition (C1) and formulation (F) according to the present invention may contain a biologically active agent.

[0110] Among the active ingredients that may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention, mention may be made of: Vitamins and their derivatives, in particular retinol (vitamin A) and its esters (e.g., retinyl palmitate), ascorbic acid (vitamin C) and its esters, sugar derivatives of ascorbic acid (e.g., ascorbyl glucoside), tocopherols (vitamin B), Vitamin E) and its esters (e.g., tocopheryl acetate), esters such as vitamin B3 or B10 (niacinamide and its derivatives); - Compounds with sedative properties, especially Sepicalm TM S, allantoin, bisabolol, trade name TECA TM Products sold with (Centella asiatica extract); anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (or NSAIDs), more particularly arylacetic acid (or arylalkanoic acid) derivatives and 2-arylpropionic acids (or profens), more particularly diclofenac, tiaprofenic acid, aluminoprofen, etodolac, flurbiprofen, ibuprofen, ketoprofen and naproxen; - analgesics and anti-inflammatory drugs, more specifically acetaminophen, aspirin, salicylic acid, methyl salicylate, choline salicylate, glycol salicylate, choline salicylate, l-menthol, camphor, mefenamic acid, flufenamic acid, indomethacin, protizinic acid, fentiazac, tolmetin, tiaprofenic acid, phenylbutazone, oxyphenbutazone, clofesone, pentazocine, mepirizole, hydrocortisone, cortisone, dexamethasone, fluocinolone, triamcinolone, medrysone, prednisolone, flurandrenolide, prednisone, halcinonide, methylprednisolone, fludrocortisone, corticosterone, paramethasone and betamethasone; - Antiseptics, in particular cetrimide, povidone-iodine, chlorhexidine, iodine, benzalkonium chloride, benzoic acid, nitrofurazone, benzoyl peroxide, hydrogen peroxide, hexachlorophene, phenol, resorcinol and cetylpyridinium chloride; - insecticides, more specifically trichlorfon, triflumuron, fenthion, bendiocarb, cyromazine, diflubenzuron, dicyclanil, fluazuron, amitraz, deltamethrin, cypermethrin, chlorfenvinphos, flumethrin, ivermectin, abamectin, avermectin, doramectin, moxidectin, zeta-cypermethrin, diazinon, spinosad, imidacloprid, nitenpyram, pyriproxyfen, fipronil, cythionate, lufenuron, selamectin, milbemycin oxime, chlorpyrifos, coumaphos, propetamphos, alpha-cypermethrin, high-cis-cypermethrin, ivermectin, diflubenzuron, cyclodiene, carbamates and benzoylureas; antibacterial agents, in particular sulfonamides, aminoglycosides, such as neomycin, tobramycin, gentamicin, amikacin, kanamycin, spectinomycin, paromomycin, netilmicin, polypeptides, cephalosporins, oxazolidinones, such as ciprofloxacin, levofloxacin and ofloxacin; - Moisturizing compounds, such as urea, hydroxyurea, glyceryl glucoside, diglyceryl glucoside, polyglyceryl glucoside, glycerol, diglycerol, Aquaxyl TM xylityl polyglucosides, maltitol, sorbityl polyglucosides, hyaluronic acid and their salts, for example, sodium hyaluronate, potassium hyaluronate, more specifically hyaluronic acid or hyaluronates with a molecular weight of 20 kDa to 5000 kDa, more specifically 500 kDa to 2200 kDa; - polyphenol-rich plant extracts, such as grape extract, pine extract, wine extract and olive extract; - Caffeine or its derivatives, Adiposlim TM , Adipoless TM , and compounds with slimming or fat-dissolving properties such as fucoxanthin; - N-acylprotein; N-acylpeptide (Matrixil TMetc.); N-acyl amino acids, N-acyl protein partial hydrolysates, amino acids, peptides, total protein hydrolysates; - Plant extracts, such as soybean extracts (e.g. Raffermine TM ), wheat extract (e.g., Tensine TM or Gliadine TM ), plant extracts, such as tannin-rich plant extracts and isoflavone- or terpene-rich plant extracts Freshwater or saltwater algae extracts; marine plant extracts; marine extracts, generally coral-like; essential waxes; bacterial extracts; - Ceramides; - phospholipids; - Compounds with antibacterial or cleansing properties, such as lipacide TM C8G, Lipacide TM UG, Sepicontrol TM A5; Octopirox TM or Sensiva TM SC50; - Compounds with energizing or stimulating properties, e.g., Physiogenyl TM ,,Sepicap TM Panthenol and its derivatives such as MP; - Anti-aging agents, such as Sepilift TM DPHP, Lipacide TM PVB, Sepivinol TM , Sepivital TM , Manoliva TM , Phyto-Age TM , Timecode TM or Survicode TM ; - anti-photoaging agents; active agents for protecting the integrity of the dermal-epidermal junction; active agents for increasing the synthesis of extracellular matrix components such as collagen, elastin and glycosaminoglycans; active agents that act favorably on chemical cell signals such as cytokines or physical cell signals such as integrins; - active agents that create a "heating" sensation on the skin, such as skin microcirculation activators (such as nicotinic acid derivatives) or products that create a "freshness" sensation on the skin (such as menthol and its derivatives); - Active agents that improve skin microcirculation, such as venous tonics; drainage active agents; decongestant active agents, such as extracts of ginkgo, ivy, common horse chestnut, bamboo, ruscus, raspberry, Centella asiatica, fucus, rosemary or willow; - agents for tanning or browning the skin, such as dihydroxyacetone (DHA), erythrulose, mesotartaric aldehyde, glutaraldehyde, glyceraldehyde, alloxan, ninhydrin, plant extracts, such as extracts of the red trees of the genera Pterocarpus and Baphia (such as those described in European Patent Application No. 0 971 683, such as extracts of the genera Pterocarpus santalinus, Pterocarpus osun, Pterocarpus soyauxii, Pterocarpus erinaceus, Pterocarpus indicus or Baphia nitida); agents known for their effect in promoting and / or accelerating the tanning and / or browning of human skin and / or for their effect in pigmenting human skin, such as carotenoids (more particularly beta-carotene and gamma-carotene), Carrot Oil (INCI name: Daucus carrota, Helianthus annuus sunflower oil) sold by the company Provital, which contains carotenoids, vitamin E and vitamin K; tyrosine and / or derivatives thereof, such as SunTan Accelerator by the company Provital, which contains tyrosine and riboflavin (vitamin B), known for their effect in accelerating the tanning of human skin in combination with exposure to ultraviolet light; TM products sold under the trade name Zymo Tan Complex by Zymo Line, a tyrosine and tyrosinase complex sold under the trade name Zymo Tan Complex by Zymo Line, and MelanoBronze by Mibelle, which contains acetyltyrosine. TM(INCI name: Acetyl tyrosine, monk's pepper extract (Vitex Agnus-castus)), a product sold by Unipex under the name Unipertan VEG-24 / 242 / 2002 (INCI name: Butylene glycol and acetyl tyrosine and hydrolyzed vegetable protein and adenosine triphosphate), a product sold by Sederma under the name Try-Excell, which contains an extract of mallow seeds (or loofah seeds). TM (INCI name: Oleoyl tyrosine and Luffa cylindrica (seed) Oil and oleic acid), a product marketed by Alban Muller under the trade name Actibronze TM (INCI name: Hydrolyzed wheat protein and acetyl tyrosine and copper gluconate), a product marketed by Synerga under the trade name Tyrostan TM (INCI name: Potassium caproyl tyrosine) and by Synerga under the trade name Tyrosinol (INCI name: Sorbitan isostearate, glyceryl oleate, caproyl tyrosine). InstaBronze by Alban Muller TMproducts sold under the trade name Dihydroxyacetone and acetyl tyrosine and copper gluconate (INCI name: Dihydroxyacetone and acetyl tyrosine and copper gluconate), products sold by Exymol under the trade name Tyrosilane (INCI name: Methylsilanol and acetyl tyrosine); peptides known to activate melanogenesis, such as products sold by Infinitec Activos under the trade name Bronzing SF peptide powder (INCI name: Dextran and octapeptide-5), products containing acetyl hexapeptide-1 known to have α-MSH agonist properties, such as products sold by Infinitec Activos under the trade name Melitane (INCI name: Glycerin and aqua and dextran and acetyl hexapeptide-1), and products sold by Lipotec under the trade name Melatimes Solutions. TM (INCI name: Butylene glycol, palmitoyl tripeptide-40), sugars and sugar derivatives, such as Tanositol by Provital TM (INCI name: Inositol), a product containing marine-derived oligosaccharides (guluronic and mannuronic acids chelated with magnesium and manganese ions) and marketed in Thalitan by Codif International. TM (or Phycosaccharide TM AG)(INCI name:Aqua and hydrolyzed algin (Laminaria digitata) and magnesium sulfate and manganese sulfate), a product sold under the brand name Melactiva by Alban Muller TM(INCI name: Maltodextrin, Mucuna pruriens seed extract), and flavonoid-rich compounds, such as the product sold by the company Silab under the trade name Biotanning (INCI name: Hydrolyzed citrus Aurantium dulcis fruit extract), which is known to be rich in lemon flavonoids (hesperidin type).

[0111] Examples of sunscreens optionally present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include all those listed in Annex VII of the revised European Cosmetics Regulation 76 / 768 / EEC.

[0112] The organic sunscreens optionally present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention include: benzoic acid derivatives, such as para-aminobenzoic acid (PABA), in particular monoglyceryl esters of PABA, ethyl esters of N,N-propoxy PABA, ethyl esters of N,N-diethoxy PABA, ethyl esters of N,N-dimethyl PABA, methyl esters of N,N-dimethyl PABA, butyl esters of N,N-dimethyl PABA; - Anthranilic acid derivatives such as homomenthyl-N-acetylanthranilate; - Salicylic acid derivatives such as amyl salicylate, homomenthyl salicylate, ethylhexyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropylphenyl salicylate; - Cinnamic acid derivatives such as ethylhexyl cinnamate, ethyl-4-isopropyl cinnamate, methyl-2,5-diisopropyl cinnamate, p-methoxypropyl cinnamate, p-methoxyisopropyl cinnamate, p-methoxyisoamyl cinnamate, p-methoxyoctyl cinnamate (p-methoxy-2-ethylhexyl cinnamate), 2-ethoxyethyl cinnamate, p-methoxycyclohexyl cinnamate, ethyl-α-cyano-β-phenyl cinnamate, 2-ethylhexyl-α-cyano-β-phenyl cinnamate, glyceryl di-p-methoxy-mono-2-ethylhexanoyl cinnamate; - 2,4'-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, 2,2',4,4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenylbenzophenone, 2-ethylhexyl-4'-phenylbenzophenone-2-carboxylate silates, 2-hydroxy-4-n-octyloxybenzophenone, 4-hydroxy-3-carboxybenzophenone; 3-(4'-methylbenzylidene)-d,l-camphor, 3-(benzylidene)-d,l-camphor, camphor benzalkonium methiosulfate, urocanic acid, ethyl urocanate; sulfonic acid derivatives such as 2-phenylbenzimidazole-5-sulfonic acid and their salts, and benzophenone derivatives; - Hydroxyphenyl triazine, (ethylhexyloxyhydroxyphenyl)(4-methoxyphenyl)triazine, 2,4,6-trialinino(p-carbo-2'-ethylhexyl-1'-oxy)-1,3,5-triazine, 4,4-((6-(((1,1-dimethylethyl)amino)carbonyl)phenyl)amino)-1,3,5-triazine-2,4-diyldiimino)bis(2-ethylhexyl)benzoate, 2-phenyl-5- Methylbenzoxazole, 2,2'-hydroxy-5-methylphenylbenzotriazole, 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methylphenyl)benzotriazole; dibenzazine; dianisoylmethane, 4-methoxy-4''-t-butylbenzoylmethane; triazine derivatives such as 5-(3,3-dimethyl-2-norbornylidene)-3-pentan-2-one; - diphenylacrylate derivatives such as 2-ethylhexyl-2-cyano-3,3-diphenyl-2-propenoate or ethyl-2-cyano-3,3-diphenyl-2-propenoate; - Polysiloxanes such as benzylidene siloxane malonate

[0113] Mineral sunscreens, also known as "mineral sunblocks", which may be present in the compositions (C1) and formulations (F) for topical use that are the subject of the present invention, include titanium oxide, zinc oxide, cerium oxide, zirconium oxide, yellow, red or black iron oxide, and chromium oxide. These mineral sunblocks may be micronized or not, may be surface-treated or not, and may optionally be in the form of an aqueous or oily predispersion.

[0114] The process for preparing the composition (C1) defined above comprises the following steps: step a) introducing natural mineral water, natural spring water, seawater or algae water into a tank of suitable volume at a temperature of 25°C; introducing demineralized water to obtain a desired conductivity of 300 μS cm -1 Prepare the aqueous phase by diluting to the above amount. - step b) With adequate mechanical stirring, at 25°C, the crosslinked anionic polyelectrolyte (P1) is added to the aqueous phase previously prepared, maintaining stirring until gelation of the medium is observed. - step c) With adequate mechanical stirring, at 25°C, the galactomannan (GM) is added to the gelled aqueous phase previously prepared, maintaining stirring until a homogeneous gel is observed.

[0115] The process for preparing the formulation (F) defined above comprises the following steps: step a) preparing the fatty phase (A2) by mixing all the components that make up the fatty phase (A2) in the desired proportions, this mixing step generally being carried out at a temperature between 25°C and 80°C, more preferably between 25°C and 60°C, even more preferably between 25°C and 40°C, and with mechanical stirring at a moderate speed between 50 and 100 rpm; step b) preparing a composition (C1) as described above, in particular the aqueous phase (A1) obtained at the end of step b) has a dynamic viscosity, measured at 25 °C using a Brookfield LV viscometer at a rotation speed of 6 rpm, of 200 mPa·s to 40,000 mPa·s, more preferably 1000 mPa·s to 40,000 mPa·s, even more preferably 2000 mPa·s to 40,000 mPa·s; - step c) at a temperature of from 25°C to 80°C, more preferably from 25°C to 60°C, even more preferably from 25°C to 40°C, at a moderate speed of from 50 to 400 rpm At this rate, the fatty phase (A2) is added to the composition (C1) with mechanical stirring to obtain the formulation (F).

[0116] The following examples illustrate the present invention but do not limit it in any way.

[0117] Preparation and evaluation of aqueous gels according to the present invention and comparative aqueous gels 1) Preparation of aqueous gel Four aqueous gels according to the present invention, designated (F1) to (F4), and eight comparative aqueous gels, designated (F'1) to (F'8), were prepared by the following method. Their mass ratios and components are summarized in Table 1 below.

[0118] The aqueous phase is prepared by introducing high-conductivity water and demineralized water at 25 °C in a relative ratio that allows obtaining an aqueous phase with the desired conductivity (e.g., 730 μS / cm or 3.28 mS / cm in the experimental section below). Next, the crosslinked anionic polyelectrolyte is gradually introduced into the previously prepared aqueous phase at 25 °C using moderate mechanical stirring, i.e., using an anchor-type stirring head, at a speed of 50 to 150 rpm, until a homogeneous gel is obtained. Galactomannan (GM) is added to the previously formed gel at a temperature of 25 °C while stirring using a mechanical stirrer equipped with an anchor-type stirring head. This stirring is then maintained for 10 minutes; no cooling step is necessary.

[0119] 2) Characterization of aqueous gels The properties of the aqueous gel are: - The appearance of the prepared gel is evaluated and a uniform appearance of the gel is observed at 25°C; and - determination of the dynamic viscosity of gels prepared at 25°C, It is inspected by.

[0120] The results of the characterization and measurements are shown in Table 1 below.

[0121] [Table 1]

[0122] [Table 2]

[0123] (1) Hydralixir TMLD (INCI name: water and Laminaria Digitata Extract) is a cell water derived from brown algae, Laminaria Digitata. (2) Solagum TM AX (INCI name: acacia Senegal gum and Xanthan gum) is a thickening and stabilizing agent for preparing cosmetic compositions. (3) Solagum TM Tara (INCI name: Caesalpinia Spinosa Gum) is a galactomannan with a degree of substitution of 1 / 3, used as a thickener and stabilizer for preparing cosmetic compositions. (4) Sepinov TM EMT10 (INCI name: hydroxyethyl acrylic acid / sodium acryloyldimethyl taurate copolymer) is a thickener, stabilizer and emulsifier, used in powder form in the preparation of cosmetic compositions. (5) Simulgel TM EG (INCI name: Sodium Acrylate / Sodium Acryloyldimethyl Taurate Copolymer & Isohexadecane & Polysorbate 80) is a thickener, stabilizer, and emulsifier in the form of a self-inverting inverse latex, and is used to prepare cosmetic compositions. It is used. (6) Sepigel TM 305 (INCI name: Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7) is a thickener, stabilizer and emulsifier, in the form of a self-inverting inverse latex, used to prepare cosmetic compositions. ( * ):Simugel TM The EG is in the form of a self-inverting inverse latex with a cross-linked anionic polyelectrolyte content of 40%. ( ** ):Sepigel TM305 is in the form of a self-inverting inverse latex with a cross-linked anionic polyelectrolyte content of 40%.

[0124] 3) Analysis of results 0.5% by weight of tara gum was added to Sepinov TM When used in combination with 1.5% by weight of a cross-linked anionic polyelectrolyte sold under the trade name EM10, a very viscous aqueous gel (F1) (190,000 mPa·s) can be obtained, but the addition of 1.5% by weight of Sepinov TM The aqueous gel of EMT10(F'1) only achieved a viscosity of 48,000 mPa·s.

[0125] When tara gum was replaced with a mixture of acacia gum and xanthan gum, the formation of a high-viscosity aqueous gel was not observed, and the viscosity of the obtained comparative gel (F'2) was 41,100 mPa·s, i.e., Sepinov TM It is very close to the viscosity level of the aqueous gel (F'1) obtained solely with cross-linked anionic polyelectrolyte sold under the trade name EM10.

[0126] The viscosities of the comparative gels (F'3), (F'4) and (F'5) obtained with tara gum alone at various dosages (0.5%, 1% and 1.5%, respectively) showed values ​​of 240 mPa·s, 5000 mPa·s and 41,000 mPa·s, respectively, and therefore, the viscosity of the gels obtained with 0.5% by mass of tara gum and Sepinov TM It does not reflect the viscosity levels achieved in combination with 1.5 wt. % of a cross-linked anionic polyelectrolyte sold under the trade name EM10.

[0127] Such high viscosities are also observed when tara gum is combined with cross-linked anionic polyelectrolytes of different nature, such as cross-linked copolymers based on sodium acrylate and sodium acryloyldimethyltaurate (170,000 mPa·s for aqueous gel (F2) according to the invention) or cross-linked copolymers based on acrylamide and sodium acryloyldimethyltaurate (220,000 mPa·s for aqueous gel (F3) according to the invention).

[0128] Furthermore, when comparing the viscosity of the aqueous gel according to the invention (F4) with that of the comparative aqueous gel (F'8), the synergistic effect of the combination is also demonstrated when the conductivity of the aqueous phase is higher (3.28 mS / cm for (F4) and (F'8)).

Claims

1. - Conductivity measured at 25°C is 300 microsiemens / centimeter (μS cm －１ ) to 3.28 millisiemens per centimeter (mS·cm −1 ); - crosslinked anionic polyelectrolyte (P1), at least one galactomannan (GM), Including, The crosslinked anionic polymer electrolyte (P1) is a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or completely salified in the form of its sodium salt and acrylic acid (δ) partially or completely salified in the form of its sodium salt, in which the molar ratio (γ) / (δ) is 40 / 60 or more and 90 / 10 or less, said copolymer being crosslinked with triallylamine and / or methylenebis(acrylamide); a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or completely salified in the form of a sodium salt with hydroxyethyl acrylate (ζ), in which the molar ratio (γ) / (ζ) is 30 / 70 or more and 90 / 10 or less, and which is crosslinked with triallylamine and / or methylenebis(acrylamide); a copolymer of 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid (γ) partially or completely salified in the form of a sodium salt with acrylamide (ε), in which the molar ratio (γ) / (ε) is 30 / 70 or more and 90 / 10 or less, and which is crosslinked with triallylamine and / or methylenebis(acrylamide); A composition for topical use in the form of a gel (C １ ).

2. Per 100% by mass of the composition, - The conductivity measured at 25°C is 300 microsiemens / centimeter (μS cm －１ ) to 3.28 millisiemens / centimeter (mS·cm −1 ). 93-99.4% by mass, - 0.5 to 5% by weight of the crosslinked anionic polyelectrolyte (P1), 0.1 to 2% by weight of said galactomannan (GM), The composition of claim 1 (C １ ).

3. 3. The composition according to claim 1 or claim 2, characterized in that the galactomannan has a degree of substitution of 1 / 3. １ ).

4. The composition (C) according to any one of claims 1 to 3, characterized in that the mass ratio of the galactomannan (GM) to the crosslinked anionic polyelectrolyte (P1) is 0.15 or more and 0.75 or less. １ ).

5. - a composition for topical use according to any one of claims 1 to 4 (C １ ), and a fatty phase (A2) comprising i) at least one oil and ii) an emulsifying system comprising at least one emulsifier (S1); (F) A formulation for topical use comprising:

6. Per 100% by mass of the formulation, - the composition (C １ ) in an amount of 60 to 90% by mass, - 10 to 40% by mass of the fatty phase (A2), 6. The formulation according to claim 5, characterized in that it comprises:

7. 7. Formulation according to claim 5 or 6, characterized in that the emulsifier (S1) is selected from the group consisting of alkyl polyglycoside compositions, compositions of alkyl polyglycosides and fatty alcohols, polyglycerol esters, alkoxylated polyglycerol esters, polyglycol polyhydroxystearates, polyglycerol polyhydroxystearates and alkoxylated polyglycerol polyhydroxystearates.

8. 5. A composition according to any one of claims 1 to 4, which can be administered topically to cleanse and / or protect and / or care for the skin, hair, scalp, nails, lips, eyelashes or eyebrows of the human or animal body. １ ).

9. 8. A formulation (F) according to any one of claims 5 to 7, which can be administered topically to cleanse and / or protect and / or care for the skin, hair, scalp, nails, lips, eyelashes or eyebrows of the human or animal body.

10. Composition (C) according to any one of claims 1 to 4, characterized in that it contains a bioactive agent. １ ).

11. Formulation (F) according to any one of claims 5 to 7, characterized in that it contains a biologically active agent.

Images